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TLR2 and TLR4-mediated 
inflammation in Alzheimer’s disease: 
self-defense or sabotage?
Alzheimer ’s disease (AD) is an irreversible 
disease that leads to neurodegeneration. The 
underpinning mechanisms of neuronal cell death 
are a matter of ongoing debate regarding the 
impact of accumulation of the amyloid beta (Aβ) 
peptide and post-translation modifications of the 
tau protein. However, a growing area of research 
and one that may provide a more rigorous 
account of the early changes seen in Alzheimer’s 
brains is inflammation. Brain inflammation is a 
coordinated immune response to subtle changes 
in the brain’s microenvironment indicative of 
injury and disease. Neuroinflammation can be 
either short lived or chronic and lead to changes 
in brain structure and its neurochemistry. In 
AD, the ability of the brain to self-regulate 
inflammatory signals is compromised and leads to 
a chronic and deleterious inflammatory response. 
Understanding the molecular entities that are 
involved in neuroinflammation in AD will open the 
door to much needed novel therapeutic strategies. 
However, this is a cautionary tale with respect 
to the timing and exact nature of the proposed 
therapeutic strategy. In this perspective article, we 
will briefly introduce the current view of the dual 
nature of Toll-like receptor (TLR) 2 and TLR4-driven 
inflammation in AD and highlight why we believe 
that modulating the inflammatory status within 
a defined time window might provide a better 
therapeutic concept than globally supressing it for 
a prolonged time. 
Molecular studies as well as neuropathological 
studies of mouse tissue and post-mortem patient 
brains have provided striking evidence for a 
correlation between inflammation and AD. In 
addition, clinical studies have proposed that 
individuals with high levels of the inflammatory 
markers have an increased risk of developing 
dementia (Dziedzic, 2006). However, the exact 
nature of the relationship between AD and 
inflammation is still not well understood. While 
some studies claim that inflammation contributes 
to disease development and progression, others 
suggest that it is merely a result of ongoing 
neurodegeneration. 
This controversy has growing relevance given 
the increase in anti-inflammatory drugs being 
proposed for managing complex neurological 
disorders, such as AD. In the context of dementia 
and AD, non-steroidal anti-inflammatory drugs 
(NSAIDs) have been tr ialed as a potential 
treatment option. However, despite promising 
initial epidemiological data, meta-analyses and 
clinical trials showed little to no therapeutic 
benefits and an increased frequency of adverse 
health effects. We postulate that this lack of robust 
effects is likely to be caused by an inappropriate 
timing of the intervention. Notably, most studies 
have investigated the impact of NSAIDS on the 
elderly when a more targeted approach within 
a finite time window may have proven more 
successful. We suggest that anti-inflammatory 
drugs should be administered before the chronic 
phase and diagnosis of AD through clinical 
presentation (Figure 1A). This could be achieved 
by using advanced neuroimaging technology to 
provide direct measurement of brain inflammation 
(e.g., ultra-high field imaging coupled with iron 
oxide nanoparticle injection), or an indirect 
measurement via blood-brain barrier permeability.
From neurobiochemical point of view, acute and 
chronic neuroinflammation is often attributed 
to an activation of TLRs. TLRs are type I integral 
membrane receptors composed of an extracellular 
domain,  a  transmembrane domain,  and a 
cytoplasmic domain where the extracellular 
N-terminal end contains a leucine-rich binding 
domain for ligands.
The TLR family is involved in innate immune 
responses and it  oversees the recognition 
o f  a  b r o a d  r a n g e  o f  p a t h o g e n - d e r i v e d 
molecules (pathogen associated molecular 
patterns). In addition, TLRs also respond to 
a variety of other molecules that indicate 
tissue damage (danger-associated molecular 
patterns)  inc luding serum amyloid A and 
A β .  A c t i vat i o n  o f  T L R s  v i a  b o t h  d a n ge r-
associated molecular patterns and pathogen 
associated molecular patterns culminates in 
activation of the prototypic, pro-inflammatory 
transcription factor nuclear factor-κB (NF-κB) 
and induces local inflammation. Notably, many 
target genes of NF-κB including tumour necrosis 
factor alpha, interleukin 1 beta (IL-1β) and IL-8 
are mediators of inflammation thereby generating 
an inflammatory feed forward loop (Figure 1B). 
In addition, TLR-signaling also involves activation 
of c-Jun N-terminal kinases (JNK), extracellular 
signal-regulated kinases 1/2 (ERK1/2), and p38 
that in turn activate activator protein 1 (AP1) 
with additional mediators of inflammation 
as target genes including but not limited to 
IL-2 and IL-5. Expression of TLRs is not limited 
to immune-competent cells with many TLRs 
expressed in neurons, microglia, astrocytes, and 
oligodendrocytes (Bsibsi et al., 2002). Importantly, 
microglia have been reported to express a wide 
repertoire of TLRs with TLR2 and TLR4 being 
expressed constitutively and at high levels. This is 
pertinent to the study of AD given the increasing 
evidence for a pivotal role of microglia in disease 
initiation, progression, and maintenance (Landreth 
and Reed-Geaghan, 2009).  This microglia-
mediated, and NF-κB-dependent regulation 
of neuronal homeostasis can at least partly be 
attributed to TLR2 and TLR4 (Kielian, 2006). In the 
context of brain homeostasis, physiological activity 
of microglia can induce NF-κB activation and this 
can contribute to neuroprotection (Kaltschmidt 
et al., 2005). Importantly, subtle changes in NF-
κB activity can result in neurodegeneration 
(Kaltschmidt et al., 2005). 
Thus, both the strength of the inflammatory 
molecular response and the contribution of 
individual cellular players evidently plays an 
important role in neuronal cell death. 
Biochemical and genetic in vivo approaches 
alongside a multitude of in vitro studies provided 
strong evidence that Aβ can activate NF-κB and 
drive neuroinflammation in a TLR2 and TLR4 
dependent manner (Song et al., 2011; Liu et 
al., 2012). It has been reported that TLR2 is 
expressed at mRNA and protein levels in both 
animal models of dementia and human samples, 
although these observations are contested. 
These discrepancies may indicate a coordinated 
timeline of TLR2 expression and activation from 
initiation to symptomatic presentation of AD. 
Functional studies have demonstrated that in vitro 
activation of TLR2 increases microglial uptake of 
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exogenous Aβ. This contrasts with other reports 
indicating that inhibition of TLR2 activation in 
vitro and in vivo suppresses amyloid pathology. 
The in vivo datasets, suggestive of a beneficial 
TLR2 contribution, arise from work using mice 
that overexpress amyloid precursor protein and 
presenilin 1 (APP/PS1). These data highlight an 
impact of a 7-month intervention with an anti-
TLR2 antibody administered prior to cognitive 
impairment in this model. Follow up studies using 
the same AD model and a TLR2–/– mouse revealed 
that cognitive decline is accelerated in the TLR2–/–/
APP-PS1 mice compared to the APP/PS-1 mice. 
These deficits could be restored by viral induction 
of TLR2 expression prior to the cognitive decline 
(circa 3 months). Interestingly, TLR2-dependent 
JNK/NF-κB signaling has been linked to the 
inflammatory response to Aβ. However, singling 
out TLR2 as the main protagonist would be wrong 
as all TLRs can contribute to NF-κB signaling in a 
complementary manner. 
Animal  studies  us ing transgenic  AD mice 
coupled with modulat ion of  TLR4 act iv ity 
have reported a multitude of outcomes. TLR4 
ablation through genetic manipulation led 
to enhanced Aβ deposition and worsening 
cognitive outcomes compared to control animals. 
Conversely, long-term mild stimulation of TLR4 
via lipopolysaccharide administration for 3 
weeks prior to onset of neurological deficits, 
improved cognitive performance in a tau mouse 
model of AD. This contrasts with studies where 
in vitro activation of TLR4 reduced microglial Aβ 
clearance through CD36 activity as well as with 
the increased expression of TLR4 in post-mortem 
tissue from AD patients. Collectively, the roles of 
TLR2/TLR4 are likely to be dynamically regulated 
and have considerable impact (both positive and 
negative) on cognitive outcomes. In this respect, 
TLR4 activation would be a favourable target in the 
acute phase in contrast to the chronic situation 
(Huang et al., 2017). Notably, signaling via TLRs is 
known to be a subject of considerable crosstalk 
(Tan et al., 2014) including a cross-coupling 
between TLR2 and TLR4. Thus, a similar strategy 
could be applied in modulating the activity of TLR2 
signaling. Briefly, such therapeutic approach could 
involve activating TLR2 and TLR4 in the acute 
phase whilst suppressing it in the chronic phase. 
As surface receptors,  both TLR2 and TLR4 
represent promising and easily accessible drug 
targets. This has been explored in a multitude 
of preclinical models of AD. Repeated systemic 
in ject ions  of  the  b iased  agonist  o f  TLR4 
monophosphorylic lipid A in the APPswe/PS1 
mouse model of AD resulted in a significant 
reduction in Aβ load in the brain of and enhanced 
cognitive function. In addition, TAK-242, a 
specific inhibitor of TLR4 signaling, showed 
similar beneficial effects in the same mouse 
model. In addition to these well characterized 
drug candidates, several compounds believed 
to inhibit TLR4 signaling including α-mangostin, 
gerani in,  osmotin,  and berberine showed 
promising outcomes in l ipopolysaccharide 
induced mouse models of AD. However, the exact 
mode of action of these compounds is still to be 
clarified. In contrast to TLR4, there is no specific 
chemical inhibitor of TLR2 signaling. Nevertheless, 
intranasal administration of a peptide blocking 
the TLR2-interacting domain of MyD88 resulted 
in a reduced microglial activation and improved 
memory and learning in a 5XFAD mouse model of 
AD. 
Overal l ,  a temporal  profi le for AD related 
inflammation is emerging that precedes the onset 
of clinical symptoms. For the early preclinical 
phase, our knowledge is limited and largely 
comes from animal studies. However, clinical 
imaging has begun to reveal some insights into 
human pathology. Late stage inflammation is 
predominantly associated with plaque deposition, 
whereby the hallmark Aβ plaques are sites of 
[Downloaded free from http://www.nrronline.org on Monday, March 15, 2021, IP: 82.20.212.126]
NEURAL REGENERATION RESEARCH｜Vol 16｜No. 8｜August 2021｜1553
recurrent inflammation including an array of 
cellular phenotypes and associated inflammatory 
markers including high and constitutive activity of 
NF-κB.  
Summar y  and conc lus ions :  In  summar y, 
the research field of inflammation is rapidly 
expanding in the context of neurodegenerative 
d iseases .  The  current  ev idence  presents 
snapshots in time of the cellular players and 
their production of inflammatory biomarkers. 
This is an underestimation of the complexities 
of inflammatory processes within the brain 
involved in development and progression of 
neurodegenerative disorders that might have 
resulted in the failure of NSAID based prevention 
and treatment strategies in AD. We postulate 
that inflammation has an intrinsically dual role in 
AD. In the acute phase, TLR2 and TLR4-mediated 
inflammation in the brain represents a self-defence 
mechanism which affords protection. Therefore, 
a global inhibition of inflammatory signaling as a 
preventive measure during the acute phase might 
not be only ineffective but could even counteract 
regenerative processes. In contrast, uncontrolled 
and continuous high levels of inflammation 
resulting from the feed-forward inflammatory loop 
mediated by TLR2 and TLR4 are neurodegenerative 
and causative in the disease progression. Together 
this creates a therapeutic window aiming to 
prevent the switch from the acute to the chronic 
phase before clinical presentation of AD to slow 
down disease progression. The challenge for the 
Alzheimer’s research community now will be 
to accurately identify this window in a clinically 
relevant patient population. 
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Figure 1 ｜ Proposed relationship between inflammation and brain atrophy and proinflammatory signaling 
induced by TLR2 and TLR4.
(A) A proposed temporal schematic of inflammatory status and disease progression in Alzheimer’s disease 
(AD). This profile indicates the progressive nature of a degeneration disease with age as indicated by brain 
atrophy (orange line, right axis), AD highlights a likely diagnosis of AD through clinical presentation. Alongside 
brain atrophy, inflammatory status is mapped (blue line, left axis). Here, an initial increase in inflammatory 
status is observed to counteract disease related damage. This increase is curtailed by the immune system 
and represents the ‘good’ inflammation (green shaded area). However, in patients, a secondary increase is 
observed. This escalates unchecked by the immune system and subsequently contributes to the degenerative 
processes. This ‘bad’ inflammation is indicated by the pink shaded area. This leaves a discrete therapeutic 
window, in which targeting the immune response may be beneficial for neurodegenerative diseases such as 
AD. (B) Proinflammatory feed forward loops mediated by TLR2 and TLR4. In AD, Aβ and DAMPs bind to and 
activate TLR2 and TLR4. Membrane-bound TLR2 and TLR4 recruit MyD88 and TRAF6 into to complex. This leads 
to the activation of TAK1 and in turn of the IKK complex composed of IKKα, IKKβ and NEMO. Once activated by 
upstream signals, IKKβ phosphorylates inhibitory IκB proteins thereby mediating their proteasomal degradation. 
Degradation of IκB liberates the nuclear localisation signals of DNA binding NF-κB subunits leading to their 
nuclear translocation and transcription of the pro-inflammatory target genes including TNF-α, IL-1β and IL-
8. Once secreted, these proteins bind to their respective receptors further increasing NF-κB activity. This pro-
inflammatory loop also involves a TAK1-mediated activation of the kinases JNK, ERK1/2, and p38. This results in 
activity of the transcription factor AP1 with additional pro-inflammatory targets including IL-2, and IL-5.  
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